---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Surgical resection"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Surgical resection. Topics: Surgery for localized insulinoma: ENETS guidance, Cytoreductive surgery for advanced functioning tumors including insulinoma: ENETS guidance, Surgery and debulking for functioning pancreatic tumors including insulinoma: ESMO guideline, Resection of localized insulinoma: NANETS surgical guideline, and 11 further topics. 15 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/surgical-resection"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Surgical resection

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Surgical Resection

<a id="topic-2.2.2.1.1-1"></a>

### Surgery for localized insulinoma: ENETS guidance

> “As distinct from asymptomatic patients with NF-Pan-NET ≤2 cm, active surveillance is not appropriate for patients with insulinomas due to the presence of functioning symptoms.”
> “Surgical resection is the gold standard treatment for localised insulinomas.”
> “The main advantage of parenchyma-sparing over formal resections is represented by the excellent long-term functional outcomes. On the other hand, a major challenge is still represented by the high morbidity rate, mainly related to the risk of pancreatic fistula.”
> “Parenchyma-sparing pancreatic resections, including enucleation and central pancreatectomy, should be proposed as a first-line surgical strategy in patients with insulinoma [2b, A].”
> “A minimally invasive approach should be always considered, when technically feasible, for patients with preoperatively localised insulinomas [2a, A].”
> “Localised low-grade insulinomas are cured by radical surgery and do not require long-term follow-up [3, A].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.1-2"></a>

### Cytoreductive surgery for advanced functioning tumors including insulinoma: ENETS guidance

> “Strategies that result in a reduction of tumour bulk generally also significantly reduce patient hormonal symptoms [2b, B]. Cytoreductive surgery can be considered for patients with functioning tumours when ≥70%–90% of visible disease can be debulked.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.1-3"></a>

### Surgery and debulking for functioning pancreatic tumors including insulinoma: ESMO guideline

> “Moreover, surgery is mandatory in the presence of functioning Pan-NETs irrespective of tumour size.”
> “Functioning Pan-NETs ≤2 cm (e.g. insulinomas) represent ideal lesions to be enucleated, given that they are safely distant from the main pancreatic duct.”
> “Patients with high tumour burden of functioning Pan-NETs may benefit from debulking surgery [e.g. insulinoma, vasoactive intestinal peptide (VIP)oma], and surgery is generally recommended for this indication [IV, B].”

Source: [Pavel et al. (2020)](https://doi.org/10.1016/j.annonc.2020.03.304)

<a id="topic-2.2.2.1.1-4"></a>

### Resection of localized insulinoma: NANETS surgical guideline

> “Resection of a localized insulinoma results in a 98% biochemical cure rate with a 6% chance of recurrence at 10 years.”
> “In the case of insulinoma, the morbidity associated with an extensive pancreatic mobilization and 10% risk of non-palpable or non-visible tumors outweigh the low-risk of malignancy.”
> “Therefore, surgical exploration or blind resection of the tail of the pancreas are not recommended.”
> “Patients with a localized, biochemically confirmed, functional PNET should be resected because clinical syndromes associated with each are significant, even when small in size. Furthermore, with the exception of insulinoma, the majority have significant malignant potential.”
> “Criteria for selection of patients for enucleation have not been defined, but expert opinion suggests that enucleation should be reserved for smaller tumors, those more likely to display benign behavior (such as insulinomas or NF-PNETs <2 cm), and that are located >2–3 mm from the main pancreatic duct.”

Source: [Howe et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7029300/)

<a id="topic-2.2.2.1.1-5"></a>

### Surgery for benign and malignant insulinoma: JNETS guideline

> “Surgery is generally recommended for insulinomas; when indicated, a minimally invasive approach is preferable [40, 41]. Pancreatectomy with lymphadenectomy is recommended for malignant insulinomas [42].”

Source: [Ito et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8531106/)

<a id="topic-2.2.2.1.1-6"></a>

### Curative resection and debulking for insulinoma: clinical review

> “For single solitary insulinomas, curative surgical excision remains the treatment of choice. However, it should be performed only when the diagnosis is certain and by a surgeon who is skilled in pancreatic surgery.”
> “Complications following pancreas resection include postoperative pancreatic fistula, postpancreatectomy hemorrhage, and delayed gastric emptying together with exocrine and endocrine pancreatic insufficiency.”
> “In aggressive malignant cases, debulking of the panNEN, including locoregional lymph nodes can be considered on a case-by-case basis, particularly in an attempt to control the endogenous hyperinsulinemic hypoglycemia (54, 103, 118).”
> “If more than 90% of tumor load can be resected, palliative surgery can also be considered.”
> “However, most aggressive malignant metastatic insulinomas cannot be cured by surgery or ablation procedures alone and require supportive measures, medical antihormonal, and antitumor treatment (54).”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.1-7"></a>

### Outcomes after enucleation and pancreatic resection of insulinoma in 198 patients

> “A total of 198 patients (58.5% women; median age, 48 years) were identified.”
> “Surgical procedures included 106 enucleations (54%) and 92 pancreatic resections (46%). Mortality was nil. Rate of clinically significant pancreatic fistula was 18%. Enucleations had a higher reoperation rate compared with pancreatic resections (8.5% vs 1%; P = .02).”
> “Median follow-up was 65 months. Six patients (3%; 5 patients had neuroendocrine tumors grade G2) developed tumor recurrence. Four patients (2%) died of disease. New exocrine (1.5%) and endocrine (4%) insufficiencies were associated only with pancreatic resections.”

Source: [Crippa et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22430908/)

<a id="topic-2.2.2.1.1-8"></a>

### Perioperative morbidity of sporadic insulinoma resection over three decades

> “Eighty patients underwent surgery for sporadic pancreatic insulinoma, 50 of which were female (62%), with a median age of 50 (36-70) years.”
> “The mortality rate was 6% (n = 5), with a morbidity rate of 72%, including 24 severe complications (30%) and 35 pancreatic fistulas (44%). No differences were found between formal pancreatectomy and PSP in terms of postoperative outcome procedures. The surgery was curative in all the patients.”

Source: [de Carbonnières et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33975801/)

<a id="topic-2.2.2.1.1-9"></a>

### Long-term cure after insulinoma resection at a referral center over two decades

> “Sixty-one of 202 operated patients with pNEN had an insulinoma, 37 (61%) in group 1 and 24 (39%) in group 2.”
> “Enucleation was the most frequently performed operation (31 of 61, 51%), followed by distal resection (15 of 61, 25%) without significant differences between groups 1 and 2. The rate of relevant postoperative complications was not different between groups 1 and 2 (24% vs. 21%, p = 0.99). Two patients with benign insulinoma (1 out of each group) experienced disease recurrence and underwent a second resection. After a median follow-up of 134 (1–249) months, however, all 57 (100%) patients with benign insulinoma and 3 out of 4 patients with malignant insulinoma had no evidence of disease.”

Source: [Wiese et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10310606/)

<a id="topic-2.2.2.1.1-10"></a>

### Minimally invasive versus open resection of insulinoma

> “28 patients (37.8%) underwent an open approach, and 46 patients (62.2%) underwent an MIS approach.”
> “Resection done by a MIS approach was associated with shorter length of stay (5.0 vs. 6.5 days, p = 0.011), fewer grade III/IV surgical complications (19.6% vs. 32.1%, p = 0.15), lower 30-day readmission rates (17.4% vs. 42.9%, p = 0.034), and no cases of incisional hernia (0% vs. 14.3%%, p = 0.018) within two years post-operatively. The difference in local recurrence rates was not statistically significant (4.3% vs. 3.6%, p = 1).”

Source: [Patel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42362418/)

<a id="topic-2.2.2.1.1-11"></a>

### Long-term recurrence after insulinoma resection by MEN1 status

> “The risk of recurrence was greater among patients with MEN I (21% at 10 and 20 years) than in those without MEN I (5% at 10 years and 7% at 20 years).”

Source: [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/)

<a id="topic-2.2.2.1.1-12"></a>

### Survival with and without surgery in malignant insulinoma

> “A total of 121 patients were identified.”
> “Surgical resection was performed in 64% of patients.”
> “5-year OS was 84% and 14% for the surgery and no-surgery groups, respectively, p < 0.001.”
> “On multivariable analysis, surgical resection, male sex, and absence of metastatic disease were associated with greater overall and cancer-specific survival”

Source: [Sada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7678752/)

<a id="topic-2.2.2.1.1-13"></a>

### Surgical resection for NICTH: clinical review

> “Once NICTH is identified and a primary tumor is found, the mainstay of treatment is surgical resection, which is curative for hypoglycemia if resection is complete (63–69). Resolution of hypoglycemia has also been described in cases of subtotal resection (70). In rare instances, hypoglycemia recurs with tumor recurrence after what was thought to be complete resection (71, 72). However, in many cases, total resection is either delayed or not feasible.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.2.1.1-14"></a>

### Surgical removal and recovery in IGF-2-mediated NICTH: systematic review of published cases

> “Surgical removal was the most common treatment modality employed in 110 (47.2%) cases.”
> “Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.2.1.1-15"></a>

### Surgery among recovered and deceased patients with IGF-2-mediated NICTH

| Treatment | Recovered (n = 172) | Died (n = 51) | p-value |
| --- | --- | --- | --- |
| Surgery | “95 (55.2%)” | “15 (29.4%)” | “.002” |

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
